ACET Chief Scientific Officer Blake Aftab Buys 55,000 Shares

Blake Aftab, the Chief Scientific Officer at ACET, made a notable move by purchasing 55,000 shares of the company on June 19, 2026. This insider transaction did not involve a pre-planned purchase and underscores Aftab's confidence in the company's prospects.

Other Institutional Activity in ACET

RA Capital Management, L.P. increased its holdings in ACET by 234,375 shares, bringing its total to 1,182,624 shares valued at about $8.05 million, marking a 24.7% increase. Citadel Advisors LLC also boosted its position significantly by 274,009 shares, ending with 381,823 shares worth approximately $2.60 million, reflecting a 254.1% increase. Meanwhile, Vanguard Capital Management LLC opened a new position with 336,524 shares valued around $2.29 million. Conversely, Woodline Partners LP reduced its stake by 311,876 shares, leaving it with 313,124 shares valued at $2.13 million, indicating a 49.9% decrease.

Adicet Bio, Inc. Stock Down 9.6%

Shares of ACET traded near $8.35 on Wednesday. The company's recent trading activity has been marked by significant insider and institutional movements. While specific market cap and P/E ratio data are unavailable, the stock's activity suggests investor interest and volatility.

Insider Buying and Selling at Adicet Bio, Inc.

Apart from Blake Aftab, several other insiders have been active. On June 21, 2026, insiders including Lloyd Klickstein, Jeffrey Chodakewitz, Steve Dubin, Andrew Sinclair, Michael Grissinger, and Katie Peng each purchased 4,200 shares. These transactions were not pre-planned, indicating a broad insider confidence in the company's future.

Analysts Set New Price Targets

Analysts remain bullish on ACET. On May 5, 2026, Jefferies assumed coverage with a buy rating and set a $19 price target. HC Wainwright & Co. maintained a buy rating with a $27 target on March 23, 2026. Guggenheim also maintained a buy rating, setting a high target of $100 on March 13, 2026. The consensus among analysts is a buy recommendation, with a target mean price reflecting positive expectations.

About ACET

ACET operates in the biotechnology sector, focusing on developing treatments for various medical conditions. The company is known for its research-driven approach and is headquartered in the United States. With a team dedicated to innovation, ACET aims to bring advanced therapeutic solutions to the market.

Bottom Line

Blake Aftab's purchase of 55,000 shares in ACET showcases insider confidence in the company's future. Institutional investors have also shown significant interest, with some increasing their stakes substantially. Analysts are maintaining a positive outlook, suggesting potential growth. Investors should consider these factors, keeping in mind that insider and institutional activities are often seen as indicators of a company's prospects.